Trend — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (Q5106) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for Q5106 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.